Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HARVARD BIOSCIENCE INCHBIO · Entity 7369 | Director | June 09, 2026 | June 12, 2026 |
| Vaxxinity, Inc.VAXX · Entity 91688 | Director | June 20, 2023 | June 26, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HARVARD BIOSCIENCE INC
Report date June 09, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 58,669 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 16,556 · Balance 58,669 F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2: Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person. F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier.
F2: Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person.
F3: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026.
Vaxxinity, Inc.
Report date June 20, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 | Direct | 132,352 |
Reported balance
After 2023-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-20 · Grant · Acquired 132,352 · Balance 132,352 F1: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date. F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F2: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date.
F3: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 12, 2026 15:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-004082 · ownership.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,669 F1 · shares: Represents an award of 16,556 restricted stock units that vests in full (i) immediately prior to the Company's next annual meeting; or (ii) one year from the date of grant, whichever is earlier. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 42,113 shares of common stock beneficially owned by the Reporting Person. F3 · balance_after: On March 13, 2026, the common stock of Harvard Bioscience, Inc. underwent a reverse stock split in a ratio of 10-for-1. The 42,113 shares referenced in Footnote 2(b) were previously reported as covering 110,000 restricted stock units (which have now vested) and 311,126 shares of common stock beneficially owned by the Reporting Person. These numbers have been adjusted to reflect the stock split that occurred on March 13, 2026. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:33 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 110,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-069051 · tm2521202-3_4seq1.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 421,126 F1 · shares: Represents an award of 110,000 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 16, 2025, immediately prior to the commencement of such meeting, and (ii) July 16, 2026. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 311,126 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:22 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 45,872 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-24-001305 · form412799001ead_05232024.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,126 F1 · shares: Represents an award of 45,872 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 14, 2024, immediately prior to the commencement of such meeting, and (ii) May 21, 2025. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 265,254 shares of common stock held by the Reporting Person. Read SEC document |
| June 20, 2023 Filed Jun 26, 2023 18:35 UTC | Vaxxinity, Inc. VAXX · Entity 91688 | GrantStock option (right to buy) · Derivative | 132,352 | $0.00 Strike: $2.21 | $0.00 |
DisclosureSEC source: 0001437749-23-018537 · rdgdoc.xml · derivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,352 Underlying: Class A common stock · 132,352 shares Expires not disclosed F1 · date: These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation. F2 · derivative.exercise_date: These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date. F3 · derivative.expiration_date: These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates. Read SEC document |
| May 22, 2023 Filed May 23, 2023 20:07 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 25,554 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-23-001329 · form412799ead_05232023.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,254 F1 · shares: Represents an award of 25,554 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 15, 2023, immediately prior to the commencement of such meeting, and (ii) May 22, 2024. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 239,700 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2022 Filed May 26, 2022 20:02 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 38,259 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-22-001801 · form412799001ead_05262022.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,700 F1 · shares: Represents an award of 38,259 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2022, immediately prior to the commencement of such meeting, and (ii) May 24, 2023. F2 · balance_after: Includes (a) the award described in footnote (1) above and (b) 201,441 shares of common stock held by the Reporting Person. Read SEC document |
| January 01, 2022 Filed Jan 4, 2022 00:46 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 2,525 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-22-000031 · form412799ead_01032022.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,441 F1 · shares: Represents an award of 2,525 restricted stock units that will vest in full on the date of the Issuer's 2022 Annual Meeting of the Stockholders. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) an award of 14,400 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2021, immediately prior to the commencement of such meeting, and (ii) May 25, 2022, and (c) 184,516 shares of common stock held by the Reporting Person. Read SEC document |
| December 28, 2021 Filed Dec 29, 2021 21:18 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 1,401 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-002899 · form412799001ead_12292021.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,916 F1 · shares: Represents an award of 1,401 restricted stock units that fully vest on December 31, 2021. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) an award of 14,400 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2021, immediately prior to the commencement of such meeting, and (ii) May 25, 2022, (c) an award of 3,550 remaining unvested restricted stock units that fully vest on December 29, 2021, and (d) 179,565 shares of common stock held by the Reporting Person. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:14 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 14,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-001510 · form412799ead_05272021.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,515 F1 · shares: Represents an award of 14,400 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2021, immediately prior to the commencement of such meeting, and (ii) May 25, 2022. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) an award of 10,650 remaining unvested restricted stock units vesting in equal quarterly installments on June 30, 2021, September 30, 2021 and December 31, 2021, and (c) 172,465 shares of common stock held by the Reporting Person. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:37 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 14,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000048 · form412799ead_01062021.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,115 F1 · shares: Represents a deferred stock award of 14,200 restricted stock units which vest quarterly in equal installments on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021 and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for her service on the Issuer's Board of Directors and its Committees during 2021. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, or (ii) June 18, 2021, and (c) 140,815 shares of common stock held by the Reporting Person. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:14 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 28,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037994 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,915 F1 · shares: Represents an award of 28,100 restricted stock units that fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after June 11, 2020, immediately prior to the commencement of such meeting, and (ii) June 18, 2021. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) a restricted stock unit award of 14,475 remaining unvested restricted stock units vesting in equal quarterly installments on June 30, 2020, September 30, 2020 and December 31, 2020, and (c) 126,340 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:12 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 19,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000853 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,815 F1 · shares: Represents a deferred stock award of 19,300 restricted stock units which vest quarterly in equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for her service on the Issuer's Board of Directors and its Committees during 2020. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 19,300 restricted stock units which vest quarterly in equal installments on March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 as described in footnote 1 above, (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; and (c) 86,415 shares of common stock held by the Reporting Person. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:27 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 39,915 | $2.48 | $98,829.54 |
DisclosureSEC source: 0001209191-19-045553 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,515 F1 · balance_after: Includes (a) a deferred stock award of 1,100 restricted stock units which vest quarterly in equal installments on September 30, 2019 and December 31, 2019 as described in footnote 1 above; (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (c) a deferred stock award of 6,350 restricted stock units which vest quarterly in equal installments on September 30, 2019 and December 31, 2019; and (d) 78,965 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 1,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044019 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,600 F1 · shares: Represents a deferred stock award of 1,100 restricted stock units which vest quarterly in equal installments on September 30, 2019 and December 31, 2019. This retainer award was granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for her service on a committee of the Issuer's Board of Directors that the reporting person was appointed to following the 2019 Annual Meeting of Stockholders. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of May, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 1,100 restricted stock units which vest quarterly in equal installments on September 30, 2019 and December 31, 2019 as described in footnote 1 above; (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (c) a deferred stock award of 6,350 restricted stock units which vest quarterly in equal installments on September 30, 2019 and December 31, 2019; and (d) 39,050 shares of common stock held by the Reporting Person. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:25 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 35,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032790 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,500 F1 · shares: Represents a deferred stock award of 35,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 9,525 restricted stock units which vest quarterly in equal installments on June 30, 2019, September 30, 2019 and December 31, 2019; and (c) 35,875 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:22 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 12,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000929 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,400 F1 · shares: Represents a deferred stock award of 12,700 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for her service on the Issuer's Board of Directors and its Committees during 2019. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 12,700 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019; a (b) deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; and (c) 14,600 shares of common stock held by the Reporting Person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:21 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035658 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,700 F1 · shares: Represents a deferred stock award of 1,200 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018. This retainer award was granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for her service on a committee of the Issuer's Board of Directors that the reporting person was appointed to following the 2018 Annual Meeting of Stockholders. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of March, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 1,200 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018 as described in footnote 1 above; (b) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (c) a deferred stock award of 8,325 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (d) 5,075 shares of common stock held by the Reporting Person. Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:43 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 18,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033858 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · shares: Represents a deferred stock award of 18,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 24, 2019. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 8,325 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (c) 5,075 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 13:30 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 11,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001612 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,400 F1 · shares: Represents a deferred stock award of 11,100 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for her service on the Issuer's Board of Directors and its Committees during 2018. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 11,100 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; and (b) 2,300 shares of common stock held by the Reporting Person. Read SEC document |
| November 01, 2017 Filed Nov 1, 2017 21:11 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-058649 · doc4.xml · nonDerivative · entry 1 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · shares: Represents a deferred stock award of 2,300 restricted stock units which vests on December 31, 2017. This retainer award was granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for her service on the board and a committee of the Issuer's Board of Directors. the number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of August, rounded to the nearest 100 shares. F2 · balance_after: Includes a deferred stock award of 2,300 restricted stock units which vests on December 31, 2017. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 21:11 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 87,600 | $0.00 Strike: $3.33 | $0.00 |
DisclosureSEC source: 0001209191-17-058649 · doc4.xml · derivative · entry 2 Eade Katherine A. · CIK 0001721318 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,600 Underlying: Common Stock, par value $0.01 per share · 87,600 shares Expires 2027-10-30 F3 · derivative.exercise_date: The options vest in three equal installments on October 30, 2018, 2019 and 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.